NTRK1 and pachyonychia congenita: For example, Tanaka et al. profiled paired primary GC and GC-PC lesions in search of therapeutic targets, finding over-representation of receptor tyrosine kinase and MAP kinase pathway alterations in the metastatic lesions relative to their corresponding primary tumors; half of the genetic alterations detected in GC-PC were potentially targetable [40].